Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

Tyruko 300 mg concentrate for solution for infusion {equilateral_black_triangle}

Active Ingredient:
natalizumab
Company:  
Sandoz Limited See contact details
ATC code: 
L04AA23
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Risk Materials HCP Med Info
{arrow_left}
{arrow_right}

Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

{pdf_link}

Tyruko 300 mg concentrate for solution for infusion: Patient Alert Card

A patient alert card intended to educate patients and carers on the risk of PML whilst on natalizumab treatment and for up to 6 months afterwards, on the nature of PML and to ensure they exercise vigilance regarding its development.
{pdf_link}

Tyruko 300 mg Concentrate for Solution for Infusion: Physician’s Information and Management Guidelines

Physician Information and Management Guidelines intended to inform physicians on the risk and the nature of PML, risk factors for development of PML, its diagnosis and treatment, specific steps to be taken to minimize this risk and the identification and management of possible sequelae (e.g. immune reconstitution inflammatory syndrome [IRIS]).
{pdf_link}

Tyruko 300 mg concentrate for solution for infusion: Treatment Continuation Form

A treatment continuation form intended to educate patients and carers on the risk of PML whilst on natalizumab treatment and for up to 6 months afterwards, on the nature of PML and to ensure they exercise vigilance regarding its development.
{pdf_link}

Tyruko 300 mg concentrate for solution for infusion: Treatment Discontinuation Form

A treatment discontinuation form intended to educate patients and carers on the risk of PML whilst on natalizumab treatment and for up to 6 months afterwards, on the nature of PML and to ensure they exercise vigilance regarding its development.
{pdf_link}

Tyruko 300 mg concentrate for solution for infusion: Treatment Initiation Form

A treatment initiation form intended to educate patients and carers on the risk of PML whilst on natalizumab treatment and for up to 6 months afterwards, on the nature of PML and to ensure they exercise vigilance regarding its development.

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?

Log in or sign up to avoid further verifications.

Sandoz Limited
Company image
Address
Park View, Riverside Way, Watchmoor Park, Camberley, Surrey, GU15 3YL, UK
WWW
http://www.sandoz.uk.com
WWW
https://pvi1j.solutions.iqvia.com
Telephone
+44 (0) 1276 698020
Medical Information Direct Line
+44 (0)1276 698 101
Medical Information e-mail
[email protected]
Adverse event reporting email
[email protected]
Customer Care direct line
+44 (0)1276 698020
E-mail
[email protected]
E-mail
[email protected]